Globus Medical (GMED) Stock Forecast, Price Target & Predictions
GMED Stock Forecast
Globus Medical stock forecast is as follows: an average price target of $79.54 (represents a 6.45% upside from GMED’s last price of $74.72) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
GMED Price Target
The average price target for Globus Medical (GMED) is $79.54 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $96.00 to $61.00. This represents a potential 6.45% upside from GMED's last price of $74.72.
GMED Analyst Ratings
According to 11 Wall Street analysts, Globus Medical's rating consensus is 'Buy'. The analyst rating breakdown for GMED stock is 0 'Strong Buy' (0.00%), 9 'Buy' (81.82%), 2 'Hold' (18.18%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Globus Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 28, 2024 | Ryan Zimmerman | BTIG | $77.00 | $71.73 | 7.35% | 3.05% |
| Aug 07, 2024 | Vik Chopra | Wells Fargo | $78.00 | $70.53 | 10.59% | 4.39% |
| Jul 15, 2024 | Drew Ranieri | Morgan Stanley | $71.00 | $71.07 | -0.10% | -4.98% |
| May 29, 2024 | Ryan Zimmerman | BTIG | $72.00 | $65.49 | 9.94% | -3.64% |
| May 20, 2024 | Matt O'Brien | Piper Sandler | $80.00 | $64.40 | 24.22% | 7.07% |
| Mar 18, 2024 | Ryan Zimmerman | BTIG | $60.00 | $51.65 | 16.17% | -19.70% |
| Sep 19, 2023 | Mathew Blackman | Stifel Nicolaus | $61.00 | $53.04 | 15.01% | -18.36% |
| Jan 06, 2023 | - | Morgan Stanley | $78.00 | $71.97 | 8.37% | 4.39% |
| Dec 20, 2022 | - | Truist Financial | $85.00 | $71.36 | 19.11% | 13.76% |
| Dec 12, 2022 | - | Wells Fargo | $82.00 | $73.13 | 12.13% | 9.74% |
The latest Globus Medical stock forecast, released on Aug 28, 2024 by Ryan Zimmerman from BTIG, set a price target of $77.00, which represents a 7.35% increase from the stock price at the time of the forecast ($71.73), and a 3.05% increase from GMED last price ($74.72).
Globus Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 6 |
| Avg Price Target | - | $77.50 | $73.00 |
| Last Closing Price | $74.72 | $74.72 | $74.72 |
| Upside/Downside | -100.00% | 3.72% | -2.30% |
In the current month, the average price target of Globus Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Globus Medical's last price of $74.72. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 08, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Aug 28, 2024 | BTIG | Buy | Buy | Hold |
| Aug 13, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 15, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 29, 2024 | BTIG | Buy | Buy | Hold |
| May 09, 2024 | Barclays | Overweight | Overweight | Hold |
| Mar 18, 2024 | Truist Financial | Buy | Buy | Hold |
| Mar 18, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Mar 18, 2024 | BTIG | - | Buy | Upgrade |
| Feb 21, 2024 | Truist Financial | Buy | Buy | Hold |
Globus Medical's last stock rating was published by RBC Capital on Oct 08, 2024. The company gave GMED a "Outperform" rating, the same as its previous rate.
Globus Medical Financial Forecast
Globus Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $383.64M | $291.62M | $276.69M | $274.50M | $254.15M | $263.65M | $230.55M | $250.02M | $229.72M | $251.02M | $227.34M | $233.44M | $216.10M | $148.92M | $190.58M | $211.67M | $196.22M |
| Avg Forecast | $741.21M | $695.73M | $718.64M | $688.92M | $689.65M | $645.25M | $671.68M | $647.38M | $642.69M | $604.71M | $615.33M | $586.82M | $608.77M | $306.78M | $279.54M | $253.69M | $276.67M | $253.40M | $259.38M | $233.89M | $243.51M | $228.29M | $225.50M | $196.59M | $231.20M | $196.10M | $103.55M | $192.88M | $210.45M | $185.80M |
| High Forecast | $741.21M | $695.73M | $718.64M | $688.92M | $689.65M | $645.25M | $671.68M | $647.38M | $642.69M | $609.07M | $615.33M | $586.82M | $612.72M | $309.77M | $279.54M | $253.69M | $276.67M | $253.40M | $259.38M | $233.89M | $243.51M | $228.29M | $225.50M | $196.59M | $231.20M | $196.10M | $103.55M | $192.88M | $210.45M | $185.80M |
| Low Forecast | $741.21M | $695.73M | $718.64M | $688.92M | $689.65M | $645.25M | $671.68M | $647.38M | $642.69M | $593.09M | $615.33M | $586.81M | $598.32M | $304.18M | $279.54M | $253.69M | $276.67M | $253.40M | $259.38M | $233.89M | $243.51M | $228.29M | $225.50M | $196.59M | $231.20M | $196.10M | $103.55M | $192.88M | $210.45M | $185.80M |
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 2 | 4 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 15 | 9 | 9 | 16 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.25% | 1.04% | 1.09% | 0.99% | 1.00% | 1.02% | 0.99% | 1.03% | 1.01% | 1.11% | 1.16% | 1.01% | 1.10% | 1.44% | 0.99% | 1.01% | 1.06% |
Globus Medical's average Quarter revenue forecast for Dec 23 based on 4 analysts is $608.77M, with a low forecast of $598.32M, and a high forecast of $612.72M. GMED's average Quarter revenue forecast represents a 58.68% increase compared to the company's last Quarter revenue of $383.64M (Sep 23).
Globus Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 2 | 4 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 15 | 9 | 9 | 16 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $116.58M | $66.21M | $77.02M | $71.43M | $78.19M | $83.60M | $68.20M | $38.60M | $71.20M | $68.06M | $74.35M | $79.12M | $69.43M | $-6.84M | $42.74M | $64.04M | $55.95M |
| Avg Forecast | $205.84M | $193.21M | $199.57M | $191.31M | $191.52M | $179.19M | $186.53M | $179.78M | $178.48M | $167.93M | $170.88M | $91.41M | $169.06M | $85.19M | $77.63M | $83.10M | $41.57M | $70.37M | $72.03M | $75.54M | $67.62M | $63.39M | $62.62M | $50.24M | $64.20M | $54.46M | $28.76M | $52.87M | $58.44M | $51.60M |
| High Forecast | $205.84M | $193.21M | $199.57M | $191.31M | $191.52M | $179.19M | $186.53M | $179.78M | $178.48M | $169.14M | $170.88M | $109.69M | $170.15M | $86.02M | $77.63M | $99.71M | $49.89M | $70.37M | $72.03M | $90.65M | $67.62M | $63.39M | $62.62M | $60.28M | $64.20M | $54.46M | $28.76M | $63.44M | $58.44M | $51.60M |
| Low Forecast | $205.84M | $193.21M | $199.57M | $191.31M | $191.52M | $179.19M | $186.53M | $179.78M | $178.48M | $164.70M | $170.88M | $73.12M | $166.15M | $84.47M | $77.63M | $66.48M | $33.26M | $70.37M | $72.03M | $60.43M | $67.62M | $63.39M | $62.62M | $40.19M | $64.20M | $54.46M | $28.76M | $42.29M | $58.44M | $51.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.37% | 0.85% | 0.93% | 1.72% | 1.11% | 1.16% | 0.90% | 0.57% | 1.12% | 1.09% | 1.48% | 1.23% | 1.27% | -0.24% | 0.81% | 1.10% | 1.08% |
4 analysts predict GMED's average Quarter EBITDA for Dec 23 to be $169.06M, with a high of $170.15M and a low of $166.15M. This is 45.02% upper than Globus Medical's previous annual EBITDA (Sep 23) of $116.58M.
Globus Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 2 | 4 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 15 | 9 | 9 | 16 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $998.00K | $57.71M | $49.13M | $50.06M | $47.43M | $54.59M | $38.08M | $15.11M | $47.21M | $41.55M | $45.33M | $52.96M | $44.22M | $-20.84M | $25.95M | $45.53M | $38.31M |
| Avg Forecast | $151.57M | $134.81M | $139.32M | $131.65M | $121.44M | $109.75M | $115.75M | $105.50M | $100.72M | $88.62M | $92.79M | $50.98M | $80.02M | $73.96M | $80.90M | $46.35M | $16.27M | $70.92M | $73.08M | $42.14M | $64.71M | $61.87M | $60.94M | $30.63M | $69.64M | $41.80M | $-15.59M | $32.09M | $71.63M | $57.88M |
| High Forecast | $151.57M | $134.81M | $139.32M | $131.65M | $121.44M | $109.75M | $115.75M | $105.50M | $100.72M | $92.71M | $92.82M | $61.18M | $84.09M | $79.44M | $80.90M | $55.62M | $19.52M | $70.92M | $73.08M | $50.56M | $64.71M | $61.87M | $60.94M | $36.75M | $69.64M | $41.80M | $-15.59M | $38.51M | $71.63M | $57.88M |
| Low Forecast | $151.57M | $134.81M | $139.32M | $131.65M | $121.44M | $109.75M | $115.75M | $105.50M | $100.72M | $85.90M | $92.76M | $40.79M | $77.31M | $69.85M | $80.90M | $37.08M | $13.02M | $70.92M | $73.08M | $33.71M | $64.71M | $61.87M | $60.94M | $24.50M | $69.64M | $41.80M | $-15.59M | $25.68M | $71.63M | $57.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | 0.71% | 1.06% | 3.08% | 0.67% | 0.75% | 0.90% | 0.23% | 0.76% | 0.68% | 1.48% | 0.76% | 1.06% | 1.34% | 0.81% | 0.64% | 0.66% |
Globus Medical's average Quarter net income forecast for Dec 23 is $80.02M, with a range of $77.31M to $84.09M. GMED's average Quarter net income forecast represents a 7918.49% increase compared to the company's last Quarter net income of $998.00K (Sep 23).
Globus Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 2 | 4 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 15 | 9 | 9 | 16 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $156.21M | $120.07M | $122.42M | $118.08M | $106.58M | $106.72M | $100.75M | $106.56M | $96.44M | $107.25M | $97.89M | $96.83M | $93.30M | $84.13M | $97.31M | $95.54M | $92.08M |
| Avg Forecast | $320.20M | $300.56M | $310.45M | $297.61M | $297.93M | $278.75M | $290.16M | $279.67M | $277.64M | $261.23M | $265.82M | $134.87M | $262.99M | $132.53M | $120.76M | $122.61M | $114.77M | $109.47M | $112.05M | $111.47M | $105.20M | $98.62M | $97.42M | $66.14M | $99.88M | $84.72M | $44.74M | $120.36M | $90.91M | $80.27M |
| High Forecast | $320.20M | $300.56M | $310.45M | $297.61M | $297.93M | $278.75M | $290.16M | $279.67M | $277.64M | $263.12M | $265.82M | $161.85M | $264.69M | $133.82M | $120.76M | $147.13M | $137.73M | $109.47M | $112.05M | $133.76M | $105.20M | $98.62M | $97.42M | $79.37M | $99.88M | $84.72M | $44.74M | $144.44M | $90.91M | $80.27M |
| Low Forecast | $320.20M | $300.56M | $310.45M | $297.61M | $297.93M | $278.75M | $290.16M | $279.67M | $277.64M | $256.21M | $265.82M | $107.90M | $258.47M | $131.40M | $120.76M | $98.09M | $91.82M | $109.47M | $112.05M | $89.17M | $105.20M | $98.62M | $97.42M | $52.91M | $99.88M | $84.72M | $44.74M | $96.29M | $90.91M | $80.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.18% | 0.99% | 1.00% | 1.03% | 0.97% | 0.95% | 0.90% | 1.01% | 0.98% | 1.10% | 1.48% | 0.97% | 1.10% | 1.88% | 0.81% | 1.05% | 1.15% |
Globus Medical's average Quarter SG&A projection for Dec 23 is $262.99M, based on 4 Wall Street analysts, with a range of $258.47M to $264.69M. The forecast indicates a 68.36% rise compared to GMED last annual SG&A of $156.21M (Sep 23).
Globus Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 2 | 4 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 15 | 9 | 9 | 16 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.01 | $0.57 | $0.49 | $0.50 | $0.48 | $0.54 | $0.37 | $0.15 | $0.47 | $0.41 | $0.45 | $0.54 | $0.45 | $-0.21 | $0.26 | $0.46 | $0.39 |
| Avg Forecast | $1.11 | $0.98 | $1.02 | $0.96 | $0.89 | $0.80 | $0.85 | $0.77 | $0.74 | $0.65 | $0.68 | $0.57 | $0.58 | $0.54 | $0.59 | $0.51 | $0.56 | $0.52 | $0.53 | $0.47 | $0.47 | $0.45 | $0.44 | $0.37 | $0.51 | $0.31 | $-0.11 | $0.38 | $0.52 | $0.42 |
| High Forecast | $1.11 | $0.98 | $1.02 | $0.96 | $0.89 | $0.80 | $0.85 | $0.77 | $0.74 | $0.68 | $0.68 | $0.57 | $0.61 | $0.58 | $0.59 | $0.51 | $0.56 | $0.52 | $0.53 | $0.47 | $0.47 | $0.45 | $0.44 | $0.37 | $0.51 | $0.31 | $-0.11 | $0.38 | $0.52 | $0.42 |
| Low Forecast | $1.11 | $0.98 | $1.02 | $0.96 | $0.89 | $0.80 | $0.85 | $0.77 | $0.74 | $0.63 | $0.68 | $0.57 | $0.56 | $0.51 | $0.59 | $0.51 | $0.56 | $0.52 | $0.53 | $0.47 | $0.47 | $0.45 | $0.44 | $0.37 | $0.51 | $0.31 | $-0.11 | $0.38 | $0.52 | $0.42 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.02% | 0.97% | 0.96% | 0.89% | 0.93% | 1.01% | 0.79% | 0.32% | 1.04% | 0.92% | 1.23% | 1.06% | 1.47% | 1.84% | 0.69% | 0.88% | 0.92% |
According to 4 Wall Street analysts, Globus Medical's projected average Quarter EPS for Dec 23 is $0.58, with a low estimate of $0.56 and a high estimate of $0.61. This represents a 5742.10% increase compared to GMED previous annual EPS of $0.01 (Sep 23).
Globus Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NVRO | Nevro | $5.35 | $32.72 | 511.59% | Hold |
| NVCR | NovoCure | $16.59 | $68.92 | 315.43% | Hold |
| ATEC | Alphatec | $8.36 | $16.94 | 102.63% | Buy |
| OFIX | Orthofix Medical | $17.33 | $31.00 | 78.88% | - |
| IRTC | iRhythm | $81.44 | $121.17 | 48.78% | Buy |
| LIVN | LivaNova | $49.01 | $70.50 | 43.85% | Buy |
| CNMD | CONMED | $70.47 | $96.00 | 36.23% | Buy |
| NARI | Inari Medical | $48.93 | $66.11 | 35.11% | Buy |
| BRKR | Bruker | $59.35 | $73.75 | 24.26% | Buy |
| INSP | Inspire Medical Systems | $192.71 | $238.00 | 23.50% | Buy |
| PODD | Insulet | $237.44 | $270.93 | 14.10% | Buy |
| ITGR | Integer | $126.53 | $138.00 | 9.07% | Buy |
| GMED | Globus Medical | $74.72 | $79.54 | 6.45% | Buy |
| GKOS | Glaukos | $131.38 | $119.33 | -9.17% | Buy |
GMED Forecast FAQ
Is Globus Medical a good buy?
Yes, according to 11 Wall Street analysts, Globus Medical (GMED) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 81.82% of GMED's total ratings.
What is GMED's price target?
Globus Medical (GMED) average price target is $79.54 with a range of $61 to $96, implying a 6.45% from its last price of $74.72. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Globus Medical stock go up soon?
According to Wall Street analysts' prediction for GMED stock, the company can go up by 6.45% (from the last price of $74.72 to the average price target of $79.54), up by 28.48% based on the highest stock price target, and down by -18.36% based on the lowest stock price target.
Can Globus Medical stock reach $110?
GMED's average twelve months analyst stock price target of $79.54 does not support the claim that Globus Medical can reach $110 in the near future.
What are Globus Medical's analysts' financial forecasts?
Globus Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.65B (high $2.65B, low $2.65B), average EBITDA is $737M (high $737M, low $737M), average net income is $452.44M (high $452.44M, low $452.44M), average SG&A $1.15B (high $1.15B, low $1.15B), and average EPS is $3.3 (high $3.3, low $3.3). GMED's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.84B (high $2.84B, low $2.84B), average EBITDA is $789.92M (high $789.92M, low $789.92M), average net income is $557.35M (high $557.35M, low $557.35M), average SG&A $1.23B (high $1.23B, low $1.23B), and average EPS is $4.07 (high $4.07, low $4.07).
Did the GMED's actual financial results beat the analysts' financial forecasts?
Based on Globus Medical's last annual report (Dec 2022), the company's revenue was $1.02B, which missed the average analysts forecast of $1.02B by -0.05%. Apple's EBITDA was $313.82M, beating the average prediction of $259.51M by 20.93%. The company's net income was $190.17M, missing the average estimation of $202.4M by -6.04%. Apple's SG&A was $432.12M, missing the average forecast of $447.76M by -3.49%. Lastly, the company's EPS was $1.89, missing the average prediction of $2.08 by -9.08%. In terms of the last quarterly report (Sep 2023), Globus Medical's revenue was $383.64M, beating the average analysts' forecast of $306.78M by 25.05%. The company's EBITDA was $116.58M, beating the average prediction of $85.19M by 36.84%. Globus Medical's net income was $998K, missing the average estimation of $73.96M by -98.65%. The company's SG&A was $156.21M, beating the average forecast of $132.53M by 17.87%. Lastly, the company's EPS was $0.01, missing the average prediction of $0.54 by -98.15%